Scarica l'app Stockscreener
0.9077
1.25%
-0.0109
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9185
Aprire:
$0.9138
Volume 24 ore:
1.88M
Relative Volume:
0.53
Capitalizzazione di mercato:
$273.29M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-2.4531
EPS:
-0.37
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
-9.30%
1M Prestazione:
-3.35%
6M Prestazione:
-50.97%
1 anno Prestazione:
+134.37%
Intervallo 1D:
$0.891
$0.9381
Intervallo di 1 settimana:
$0.8534
$1.02
Portata 52W:
$0.36
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Confronta OCGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| OCGN | 0.9081 | 273.29M | 0 | -63.08M | -72.53M | -0.37 |
| VRTX | 449.74 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.30 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Ocugen: Q3 Earnings Snapshot - New Haven Register
Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Ocugen Inc. - Quantisnow
HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks
Navigating 4 Analyst Ratings For Ocugen - Benzinga
Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com
Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia
Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks
Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool
OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks
Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report
Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks
Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Ocugen
Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance | OCGN Stock News - StockTitan
Ocugen (NASDAQ:OCGN) soars 19% this week, taking one-year gains to 193% - Simply Wall St
A Preview Of Ocugen's Earnings - Benzinga
Ocugen Secures $30 Million In Debt Funding - citybiz
Ocugen Secures $30 Million in Debt Funding - Ocugen
Ocugen, Inc. Secures $30 Million in Debt Funding - Marketscreener.com
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):